risk patients, where an early SRT was associated with better cancer control (all p<0.01). Conversely, this effect was not evident in the very low-and very high-risk patients, where PSA level at SRT was not significantly associated with the risk of metastasis (all p>0.05) CONCLUSIONS: We developed a risk stratification tool that identified five prognostic risk groups. The early SRT administration provides better cancer control in low-, intermediate-, and high-risk patients. On the other hand, very low-(undetectable PSA after RP, Gleason score 7, and pT3a) and very high-risk patients (PSA persistence after RP and Gleason score 8) do not benefit from an early treatment administration.
INTRODUCTION AND OBJECTIVES: Estimating the risk of competing mortality is of importance in tailoring optimal individual management strategies in patients with early prostate cancer. Patients selected for radical prostatectomy at an age of 70 years or older, a stricter selection for good risks may influence the prognostic significance of individual risk factors for competing mortality. No generally accepted tool is available in order to predict competing mortality in in this particular population.
METHODS: Using proportional hazard models for the subdistribution of competing risks according to Fine and Gray, we studied 2961 consecutive patients treated at our institution between 1992 and 2007 in order to determine which parameters predict competing mortality in patients selected for radical prostatectomy at an age of 70 years or older and compared the prognostic impact of individual parameters with that in their younger counterparts. The mean follow-up was 11.2 years.
RESULTS: Three common diseases (diabetes mellitus, chronic lung disease and other cancer) which predicted competing mortality in younger men were no predictors of competing mortality in men selected for radical prostatectomy at an age of 70 years or older (hazard ratios, HRs, lower than 1). Beside age (HR per year 1.08, p¼0.0255), peripheral vascular disease (HR 2.33, p¼0.0195), cerebrovascular disease (HR 2.23, p¼0.0242), American Society of Anesthesiologists (ASA) physical status class 3 (HR 2.19, p<0.0001), current smoking (HR 2.18, p¼0.0098) and lower or unknown level of education (HR 2.07, p¼0.0002) were independent predictors of competing mortality in patients aged 70 years or older. With adding one risk point for each of these parameters, the resulting score compared favorably with five conventional comorbidity measures (Akaike information criterion 1425 versus a range between 1452 for the unweighed Charlson score and 1460 for the modified Lee mortality index). CONCLUSIONS: Conclusions: Combining these five conditions in a score might provide a superior comorbidity measure in patients undergoing radical prostatectomy at an age of 70 years or older. (RP) . The aim of our study was to assess the impact of depression and anxiety on functional outcome in patients undergoing RP for prostate cancer (PCa).
Source of
METHODS: A total of 3890 patients who underwent RP between 2004 and 2016 were analyzed. Patients with adjuvant radiation within three or twelve months after RP were excluded. For erectile function (EF) assessment, additional exclusion criteria consisted of androgen deprivation therapy (ADT) within three or twelve months after RP, preoperative erectile dysfunction and none or only unilateral nerve sparing. Baseline depression and anxiety were assessed using the Patient Health Questionnaire-(PHQ-) 4 and categorized into 0-2 (normal), 3-5 (mild) and 6 (moderate to severe) points. Urinary continence (UC) was defined as the use of zero or 1-safety pad per 24 hours. Recovery of EF was defined as a score of 3 points in the second question of the IIEF-5 questionnaire: 00 (...)how often were your erections stiff enough for penetration? 00 . Multivariable logistic regression analyses adjusted for age, BMI, pathological tumor stage and nervesparing technique (bi-vs. unilateral vs. none; only in UC analysis) were used to assess the impact of depression and anxiety on UC and EF.
RESULTS: Overall 1-week UC rates were 20.6%, 18.5% and 13.1% for PHQ-4 scores 0-2, 3-5 and 6. For the same groups, the rates were 75.1%, 73.7% and 69.4% for 3-months and 84.2%, 86% and 75% for 1-year UC. Multivariable regression analyses confirmed the adverse impact of a higher PHQ-4 score on 1-week and 1-year UC. Odds ratio for 1-week, 3-months and 1-year UIC were 1.86, 1.42 and 1.99 for patients with PHQ-4 scores 6 (p¼ 0.003, 0.1 and 0.02). EF rates at 3-months were 47.9 %, 43.1% and 47.4% for PHQ-4 scores 0-2, 3-5 and 6. For the same groups, 1-year EF recovery rates were 63.7%, 57.9% and 58.6%. No statistically significant difference was found either in uni-or in multivariable analyses. However, we observed a significantly higher use of PDE-5-inhibitors (PDE-5-I) and intracavernous injection therapies (ICI) among men with PHQ-4 score of 6.
CONCLUSIONS: A higher PHQ-4 score, representative for depression and anxiety, is significantly associated with worse 1-week and 1-year UC. We did not found a correlation between depression and anxiety and EF recovery, however men with higher PHQ-4 scores were more likely to use erectile dysfunction treatment. Therefore, further studies and higher patient samples are necessary. 

INTRODUCTION AND OBJECTIVES:
The optimal primary treatment for men with clinically high-risk prostate cancer (PCa) is controversial as both radical prostatectomy (RP) and radiotherapy (RT) are associated with potential advantages and disadvantages. Our objective was to compare the overall mortality-free survival of high-risk PCa patients treated with primary RP vs. primary RT with neoadjuvant/ adjuvant androgen deprivation therapy [ADT], within the National Cancer Data Base (NCDB).
METHODS: Within the NCDB, a total of 87,875 high-risk PCa patients fulfilled our pre-specified inclusion criteria (53, 197 in RP group and 34, 678 in RT+ADT group) . We employed an instrumental variable analysis (IVA) approach using the yearly rate of RP as the instrument, to mitigate the impact of both observed and unobserved confounders. Multiple sensitivity analyses were performed, including stratification for age, comorbidity, ADT utilization and high dose (>75.6 Gy) RT. In addition, the overall mortality-free survival of RP was compared to that of RT reported in three recently published randomized controlled trails (RCTs), after selecting only RP patients who fitted inclusion/exclusion criteria of these RCTs. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e985
